Suppression of spermatogenesis by etonogestrel implants with depot testosterone: Potential for long-acting male contraception

被引:55
作者
Anderson, RA
Kinniburgh, D
Baird, DT
机构
[1] Univ Edinburgh, Ctr Reproduct Biol, MRC, Human Reproduct Sci Unit, Edinburgh EH3 9ET, Midlothian, Scotland
[2] Univ Edinburgh, Ctr Reproduct Biol, Contracept Dev Network, Edinburgh EH3 9ET, Midlothian, Scotland
关键词
D O I
10.1210/jc.87.8.3640
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coadministration of a progestogen with testosterone increases the degree of suppression of spermatogenesis and is one approach to the development of hormonal male contraception. Depot formulations may allow a reduction in dosage, minimizing adverse effects. We have investigated the effects of a sc implant containing the progestogen etonogestrel (Implanon) with depot testosterone on spermatogenesis in normal men. Twenty-eight men were randomized to receive either one or two etonogestrel implants, removed after 24 wk. All men additionally received 400 mg testosterone pellets on d 1 and at 12 wk. Four men withdrew during the study, three because of side effects. Testosterone concentrations remained within the physiological range during treatment, although they were overall slightly reduced, compared with pretreatment. Both groups showed marked suppression of spermatogenesis, nine men in each group achieving azoospermia (64% and 75% in the one- and two-implant groups, respectively). Sperm concentrations in 13/14 men in the two-implant group fell to 0.1 X 10(6)/ml or less. Spermatogenic suppression was more variable in the one-implant group, with partial recovery in three men. Incomplete suppression of spermatogenesis in the one-implant group was associated with less complete suppression of gonadotropins. There were no significant changes in body weight, hemoglobin, hematocrit, or high-density lipoprotein cholesterol concentrations during treatment. These data demonstrate that etonogestrel implants with depot testosterone provide effective suppression of spermatogenesis with reduced metabolic effects and are, therefore, a promising approach to the development of long-acting yet reversible male contraception.
引用
收藏
页码:3640 / 3649
页数:10
相关论文
共 52 条
[1]   Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression [J].
Anawalt, BD ;
Herbst, KL ;
Matsumoto, AM ;
Mulders, TMT ;
Coelingh-Bennink, HJT ;
Bremner, WJ .
FERTILITY AND STERILITY, 2000, 74 (04) :707-714
[2]  
Anawalt BD, 1999, J ANDROL, V20, P407
[3]   Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study .2. Pharmacokinetics and pharmacokinetics of once weekly administration of testosterone enanthate [J].
Anderson, RA ;
Wu, FCW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) :896-901
[4]   7α-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men [J].
Anderson, RA ;
Martin, CW ;
Kung, AWC ;
Everington, D ;
Pun, TC ;
Tan, KCB ;
Bancroft, J ;
Sundaram, K ;
Moo-Young, AJ ;
Baird, DT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3556-3562
[5]   Inhibin B in seminal plasma: testicular origin and relationship to spermatogenesis [J].
Anderson, RA ;
Irvine, DS ;
Balfour, C ;
Groome, NP ;
Riley, SC .
HUMAN REPRODUCTION, 1998, 13 (04) :920-926
[6]   THE EFFECTS OF EXOGENOUS TESTOSTERONE ON SEXUALITY AND MOOD OF NORMAL MEN [J].
ANDERSON, RA ;
BANCROFT, J ;
WU, FCW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (06) :1503-1507
[7]  
[Anonymous], 1990, Lancet, V336, P955
[8]  
Aribarg A, 1996, FERTIL STERIL, V65, P821
[9]   COMPARISON OF A GONADOTROPIN-RELEASING-HORMONE ANTAGONIST PLUS TESTOSTERONE (T) VERSUS-T ALONE AS POTENTIAL MALE CONTRACEPTIVE REGIMENS [J].
BAGATELL, CJ ;
MATSUMOTO, AM ;
CHRISTENSEN, RB ;
RIVIER, JE ;
BREMNER, WJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (02) :427-432
[10]   PREGNANCIES ASSOCIATED WITH SPERM CONCENTRATIONS BELOW 10 MILLION-ML IN CLINICAL STUDIES OF A POTENTIAL MALE CONTRACEPTIVE METHOD, MONTHLY DEPOT MEDROXYPROGESTERONE ACETATE AND TESTOSTERONE ESTERS [J].
BARFIELD, A ;
MELO, J ;
COUTINHO, E ;
ALVAREZSANCHEZ, F ;
FAUNDES, A ;
BRACHE, V ;
LEON, P ;
FRICK, J ;
BARTSCH, G ;
WEISKE, WH ;
BRENNER, P ;
MISHELL, D ;
BERNSTEIN, G ;
ORTIZ, A .
CONTRACEPTION, 1979, 20 (02) :121-127